Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) experienced a decline of 1.38% on September 19, with a trading volume of 492 million yuan, indicating a potential shift in investor sentiment towards innovative drug investments [1] Group 1: Fund Performance - The fund's latest net asset value is calculated at 5.326 billion yuan [1] - Since its inception on March 26, 2025, the fund has achieved a return of 58.14% [1] - Over the past month, the fund has seen a return of -4.25% [1] Group 2: Fund Activity - On the same day, the fund's shares increased by 1 million, bringing the total shares to 3.368 billion [1] - In the last 20 trading days, the fund's shares have increased by 48 million [1] Group 3: Management and Benchmark - The fund is managed by ICBC Credit Suisse Asset Management Company, with managers Liu Weilin and Jiao Wenlong [1] - The performance benchmark for the fund is the adjusted return rate of the Guotai Junan Hong Kong Stock Connect Innovative Drug Index [1]
9月19日港股通创新药ETF工银（159217）份额增加100.00万份
Xin Lang Cai Jing·2025-09-22 01:11